{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:25:26Z","timestamp":1785882326977,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Part of this work was supported by a small research grant from 340B Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-024-12188-1","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:44:31Z","timestamp":1738025071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jianhui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"12188_CR1","unstructured":"340B Drug Pricing Program | Official web site of the U.S. Health Resources & Services Administration [Internet]. Hrsa.gov. 2017. Available from: https:\/\/www.hrsa.gov\/opa\/index.html."},{"key":"12188_CR2","unstructured":"\u201cThe 340B drug discount program,\u201d Health Affairs Health Policy Brief, September 14, 2017."},{"issue":"9","key":"12188_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamadermatol.2015.1005","volume":"151","author":"J Albrecht","year":"2015","unstructured":"Albrecht J, Mudahar S. The Reach of the 340B Drug Pricing Program. JAMA Dermatol. 2015;151(9):923.","journal-title":"JAMA dermatology"},{"key":"12188_CR4","unstructured":"Mulligan K. The 340B Drug Pricing Program: Background, ongoing challenges and recent developments [Internet]. Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California; 2021 Oct [cited 2024 Feb 5] p. 1\u201315. Available from: https:\/\/healthpolicy.usc.edu\/wp-content\/uploads\/2022\/07\/USC_Schaeffer_340BDrugPricingProgram_WhitePaper.pdf."},{"issue":"11","key":"12188_CR5","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.sapharm.2021.03.010","volume":"17","author":"I Rana","year":"2021","unstructured":"Rana I, von Oehsen W, Nabulsi NA, Sharp LK, Donnelly AJ, Shah SD, et al. A comparison of medication access services at 340B and non-340B hospitals. Res Social Adm Pharm. 2021;17(11):1887\u201392.","journal-title":"Research in social and administrative pharmacy"},{"issue":"8","key":"12188_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaoncol.2015.2168","volume":"1","author":"H Kantarjian","year":"2015","unstructured":"Kantarjian H, Chapman R. Value of the 340B Drug Discount Program. JAMA Oncol. 2015;1(8):1029.","journal-title":"JAMA Oncol"},{"key":"12188_CR7","doi-asserted-by":"crossref","unstructured":"Thomas S, Schulman K. The unintended consequences of the 340B safety\u2010net drug discount program. Health Services Res. 2020;55(2):153\u20136.","DOI":"10.1111\/1475-6773.13281"},{"issue":"10","key":"12188_CR8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1377\/hlthaff.2014.0540","volume":"33","author":"RM Conti","year":"2014","unstructured":"Conti RM, Bach PB. The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities. Health Aff. 2014;33(10):1786\u201392.","journal-title":"Health affairs"},{"key":"12188_CR9","unstructured":"United States Government Accountability Office (GAO). Medicare part B drugs: Action needed to reduce financial incentives to prescribe 340B drugs at participating hospitals [Internet]. Washington, DC; 2015 Jun [cited 2024 Feb 5]. Available from: https:\/\/www.gao.gov\/products\/gao-15-442."},{"key":"12188_CR10","unstructured":"Milliman, Gomberg J, Hunter MT, Kim CJ. Commercial payers spend more on hospital outpatient drugs at 340B participating hospitals [Internet]. Milliman; 2018 Mar [cited 2024 Feb 5] p. 1\u201312. Available from: https:\/\/www.my-milliman.com\/en-GB\/insight\/commercial-payers-spend-more-on-hospital-outpatient-drugs-at-340b-participating-hospitals."},{"key":"12188_CR11","unstructured":"Blalock E. Increases in Part B drug utilization at enrolling 340B hospitals [Internet]. Berkeley Research Group; 2018 Dec [cited 2024 Feb 5] p. 1\u20135. Available from: https:\/\/media.thinkbrg.com\/wp-content\/uploads\/2020\/06\/01173352\/Part-B-Drug-Utilization-Increase-2018_cleaned.pdf."},{"key":"12188_CR12","unstructured":"Registry groupings in SEER data and statistics [Internet]. SEER. Available from: Registry Groupings in SEER Data and Statistics - SEER Registries (cancer.gov)."},{"key":"12188_CR13","unstructured":"The SEER program and data [Internet]. National Cancer Institute Division of Cancer Control & Population Sciences. Available from: The SEER Program and Data (cancer.gov)."},{"key":"12188_CR14","unstructured":"Covered entity eaily report [Internet]. HRSA Office of Pharmacy Affairs 340B OPAIS. Available from: Reports and Files (hrsa.gov)."},{"key":"12188_CR15","doi-asserted-by":"crossref","unstructured":"Sheehan DF, Criss SD, Chen Y, Eckel A, Palazzo L, Tramontano AC, et al. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer medicine [Internet]. 2019;8(1):94\u2013103. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30575329.","DOI":"10.1002\/cam4.1896"},{"key":"12188_CR16","doi-asserted-by":"crossref","unstructured":"Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER treatment data with Medicare claims. Medical care [Internet]. 2016;54(9):e55\u201364. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4981219\/.","DOI":"10.1097\/MLR.0000000000000073"},{"key":"12188_CR17","unstructured":"Fitch KV, Pelizzari PM, Pyenson BS. Cost drivers of cancer care: a retrospective analysis of Medicare and commercially insured population claim data 2004\u20132014 [Internet]. Milliman; 2016 Apr [cited 2024 Feb 5] p. 1\u201340. Available from: https:\/\/www.milliman.com\/en\/insight\/cost-drivers-of-cancer-care-a-retrospective-analysis-of-medicare-and-commercially-insured."},{"key":"12188_CR18","unstructured":"Observational research in oncology toolbox [Internet]. SEER. Available from: https:\/\/seer.cancer.gov\/oncologytoolbox\/."},{"key":"12188_CR19","unstructured":"The Medicare Payment Advisory Commission (MedPAC). Report to the Congress: Medicare and the health care delivery system. Chapter 5. Medicare part B drug and oncology payment policy issues [Internet]. 2016 [cited 2024 Feb 5] p. 117\u201354. Available from: https:\/\/www.medpac.gov\/wp-content\/uploads\/import_data\/scrape_files\/docs\/default-source\/reports\/chapter-5-medicare-part-b-drug-and-oncology-payment-policy-issues-june-2016-report-.pdf."},{"key":"12188_CR20","unstructured":"NCI-designated cancer centers - National Cancer Institute [Internet]. www.cancer.gov. 2012. Available from: https:\/\/www.cancer.gov\/research\/infrastructure\/cancer-centers."},{"key":"12188_CR21","unstructured":"Best hospitals for cancer | Rankings & Ratings | US News best hospitals [Internet]. Usnews.com. 2019. Available from: https:\/\/health.usnews.com\/best-hospitals\/rankings\/cancer."},{"key":"12188_CR22","unstructured":"Comorbidity SAS macro (2021 version) [Internet]. healthcaredelivery.cancer.gov. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/macro-2021.html."},{"key":"12188_CR23","unstructured":"NCI comorbidity index overview [Internet]. healthcaredelivery.cancer.gov. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html."},{"key":"12188_CR24","unstructured":"The Medicare Payment Advisory Commission (MedPAC). Report to the Congress: Medicare payment policy. Chapter 15. Congressional equest on health care provider consolidation [Internet]. 2020 [cited 2024 Feb 5] p. 457\u2013510. Available from: https:\/\/www.medpac.gov\/wp-content\/uploads\/import_data\/scrape_files\/docs\/default-source\/reports\/mar20_medpac_ch15_sec.pdf."},{"key":"12188_CR25","doi-asserted-by":"crossref","unstructured":"Jung J, Xu WY, Kalidindi Y. Impact of the 340B Drug Pricing Program on cancer care site and spending in Medicare. Health services research [Internet]. 2018;53(5):3528\u201348. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29355925.","DOI":"10.1111\/1475-6773.12823"},{"issue":"6","key":"12188_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMsa1706475","volume":"378","author":"S Desai","year":"2018","unstructured":"Desai S, McWilliams JM. Consequences of the 340B Drug Pricing Program. N Engl J Med. 2018;378(6):539\u201348.","journal-title":"New england journal of medicine"},{"key":"12188_CR27","unstructured":"SEER-Medicare publications by journal & year [Internet]. National Cancer Institute Division of Cancer Control & Population Sciences. Available from: SEER-Medicare Publications by Journal & Year (cancer.gov)."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-12188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-12188-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-12188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:44:43Z","timestamp":1738025083000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-12188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12188"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-12188-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the\u00a0Declaration of Helsinki. The protocol of this study was reviewed and approved by the Henry Ford Health Systems (HFHS) Institutional Review Board (IRB file No. 13140). Informed consent requirements were waived by the IRB as all data was anonymized, and all raw data that could lead to the identification of the participants was permanently removed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}